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Tofacitinib synthesis – an asymmetric challenge 
Luísa C. R. Carvalho,*[a] Ana Lourenço,[a] Luísa Maria Ferreira[a] and Paula Sério Branco[a]  
 
Abstract: Tofacitinib is a Janus activated kinase (JAK) inhibitor 
approved for the treatment of rheumatoid arthritis and active psoriatic 
arthritis. Its synthesis normally involves long synthetic sequences due 
to the chirality associated to the piperidine ring. This review is a 
comprehensive analysis of the different synthetic methods used to 
prepare this active pharmaceutical ingredient (API), covering the 
related journal and patent literature. 
1. Introduction 
Janus activated kinases (JAKs) are a family of receptor-
associated tyrosine kinases involved in several physiological 
functions such as immune response and are related to 
autoimmune and inflammatory diseases.[1],[2] JAK1/2 and TYK2 
(tyrosine kinase 2) are ubiquitously expressed and mediate 
diverse physiological processes, while JAK3 is only expressed in 
cells of the lymphohematopoietic lineage, limiting its function to 
the immune system.[1] Thus, due to the observed 
immunodeficiency resulting from the absence of JAK3, it was 
assumed that selective JAK3 inhibitors would act as potent 
immunosuppressive agents.[3] Tofacitinib (1) was developed by 
Pfizer,[4],[5] and was initially believed to be a selective JAK3 
inhibitor.[6] However, subsequent studies revealed its poor JAK3 
selectivity, also inhibiting JAK1 and JAK2.[7] Nonetheless, JAK3 
selective inhibitors seem to have a lower efficiency when 
compared to tofacitinib.[7],[8] It was claimed that the balance of JAK 
kinases inhibition casually achieved with 1, may actually improve 
its efficacy towards several therapeutic indications. 
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Figure 1. Tofacitinib (1) structure and retrosynthetic analysis. 
Tofacitinib (1) was the first JAK inhibitor approved by the US Food 
and Drug Administration for the treatment of rheumatoid arthritis 
(2012), and very recently (2017) it was approved for active 
psoriatic arthritis. It is produced and commercialized by Pfizer 
under the brand name XeljanzTM and Xeljanz XRTM (tofacitinib 
citrate). It has also been evaluated for the treatment of other 
pathologies, such as inflammatory bowel diseases and to prevent 
transplant rejection.[9],[10] 
Tofacitinib (1), [3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d] 
pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile] can be 
fragmented into two main synthons: the 4-substituted pyrrolo[2,3-
d]pyrimidine (blue) and a piperidine analogue that could lead to 
the required 3-((3R,4R)-4-methyl-3-(methylamino)piperidin-1-yl)-
3-oxopropanenitrile moiety (yellow) (Figure 1). Depending on the 
chosen strategy, the heterocyclic structure can be usually 
achieved in a fast manner from commercially available starting 
materials. However, the demand for the piperidine moiety on a 
kilogram scale, allied to its challenging structure comprising two 
asymmetric centers, required the development of efficient 
procedures that could be applied to an industrial scale. Moreover, 
its preparation usually requires a final chiral resolution step, which 
usually implies additional yield losses. Thus, most of the 
described procedures to produce 1 are focused on novel 
strategies to assemble the piperidine fragment, rather than the 
construction of the overall heterocyclic structure. Thus, it can be 
noticed the plethora of starting materials that were used to attain 
this intermediate (Figure 2). 
This review covers the literature concerning tofacitinib synthesis, 
particularly the challenges found in the asymmetric synthesis of 
the piperidine synthon, which can aid and stimulate further studies 
towards the preparation of relevant structures possessing similar 
demands. 
 
Figure 2. Starting materials described in the literature to assemble the piperidine fragment. 
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2. Piperidine moiety assembly 
The first description of 1 was disclosed in 2001 by Pfizer.[11] This 
early report discloses the preparation of 1 as the corresponding 
diastereomers without further isolation. For that purpose, 3 was 
assembled from 1-benzyl-4-methyl-piperidin-3-one (2) by 
reductive amination and was obtained as a mixture of the 
corresponding four diastereomeric forms. Compound 2 was 
prepared from a piperidone analogue or from isoprene, involving 
synthetic procedures unfeasible in large scale.[12] 
One year later, Pfizer reported the chiral salt resolution of 3, which 
was first isolated as the corresponding hydrochloric salt 4 followed 
by treatment with di-p-toluyl-L-tartaric acid (L-DTTA) or (+)-
phencyphos to obtain the corresponding salts 5 and 6 with an 
enantiomeric excess (ee) of 99% (Scheme 1).[4] Due to the simple 
strategy employed to form 1 using the benzylated derivative 5 (or 
its neutral form), most of the subsequently described 
methodologies explores the preparation of this key intermediate. 
Scheme 1. Pfizer´s approach (2002) to obtain intermediates 5 and 6.[4] 
 
In 2003, Ripin et al. (Pfizer) reported the synthesis of 4 from 
picoline (7), as an alternative starting material (Scheme 2).[13] The 
synthesis was optimized for a kilogram scale and started by the 
benzylation of 7 with benzyl chloride to produce a pyridinium salt, 
followed by reduction with sodium borohydride, to provide the 
tetrahydropyridine 8 in 94% purity. The subsequent hydroboration 
of 8 was tested under different conditions. It was verified that the 
use of BF3 etherate complex improved the reaction yield and that 
less hydrogen gas was generated during the work-up step. 
Moreover, to minimize the hydrogen liberated, the quench was 
performed in methanol in the presence of 10% calcium chloride in 
0.2 N HCl solution (pH 2). The resulting alkylborane was oxidized 
under acidic conditions (pH 2) using hydrogen peroxide, without 
requiring extended reaction times at elevated temperature. The 
authors claimed that the method required lower volumes of 
solvent compared to the procedure employing Oxone. The 
corresponding alcohol was isolated as the tosylate salt (9) in high 
purity. Due to the reaction scale, the authors selected a 
SO3.pyridine oxidation procedure to attain 2. The pH of the work-
up was kept around 10 to maximize product recovery. Product 2 
was obtained in 93% yield, being verified methylthiomethyl ether 
as the major contaminant (6%). The reductive amination was 
performed using 4 equiv of methylamine and 1 equiv of HOAc to 
guarantee a rapid and complete conversion to the imine. Although 
stated that at a bench scale NaB(OAc)3H showed an improved 
selectivity compared to NaBH4, the scale-up described in the 
experimental section was performed using NaBH4. Compound 10 
was obtained in 92% (86:14 cis:trans) along with <4% of 9 and 5-
8% of the methylthiomethyl ether as the major contaminants. The 
cis:trans ratio could be enhanced via successive recrystallizations 
to attain the hydrochloride salt 4 with a dr 97.3:2.7. As reported in 
the previous Pfizer’s patent,[4] the product resolution was 
performed using L-DTTA without the need to isolate the free base. 
Moreover, it was reinforced that resolution requires the seeding 
with a salt of high ee and that despite the optimized procedure, 
the trans isomer is never effectively eliminated.
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Scheme 2.  Pfizer’s approach (2003) to obtain 4 from picoline (7).[13]  
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Alternative starting materials were also disclosed by Pfizer 
(Scheme 3).[15],[14] The first alternative (Scheme 3, a) starts with 3-
amino-4-methyl pyridine (11), which was protected to form the 
carbamate 12 followed by hydrogenation to yield (4-methyl-
piperidin-3-yl)-carbamic acid methyl ester (13) in a 5:1 (cis:trans) 
ratio. After N-benzylation via reductive amination, reduction of cis-
(1-benzyl-4-methyl-piperidin-3-yl)-carbamic acid methyl ester using 
LiAlH4 and treatment with HCl, the hydrochloride salt 4 was 
obtained. The patent does not describe the final cis:trans ratio. The 
same procedure was employed by Biocryst Pharmaceuticals to 
attain 4, which was resolved to compound 5 in 21% yield.[16] A 
similar method was also described comprising minor changes in 
the conditions used.[17] 
A second alternative uses 4-methylpiperidine (14) to prepare the 
methyl 4-methyl-3-(methylamino)piperidine-1-carboxylate (19) 
(Scheme 3, b). The sequence comprised an electrochemical 
oxidation followed by a thermal elimination to obtain in situ 
compound 17. After the acetate cleavage to give the corresponding 
ketone, a reductive amination to insert the methylamine moiety 
yielded 19. This derivative could be envisaged as a promising 
piperidine fragment. However, the authors perceived that the 
conformational change in the six-membered ring resulted in a low 
selectivity in reductive amination. 
Scheme 3.  Pfizer’s alternative approaches (2004) to obtain 4 and 19.[14],[15] 
 
In 2007, Ruggeri et al. (Pfizer) disclose an alternative method to 
prepare intermediate 10 from compound 12 (Scheme 4).[18] The 
patent comprises the benzylation of 12 to give the corresponding 
quaternized salts 20 and 21. Asymmetric hydrogenation of 
compound 20 was performed in the presence of a particular Rh 
catalyst/phosphine ligand system used to favour the cis enrichment. 
Thus, intermediate 10 was obtained with 84% of cis product (68 % 
ee). On the other hand, 21 was first reduced to methyl (1-benzyl-4-
methyl-1,2,5,6-tetrahydropyridin-3-yl) carbamate (22), followed by 
asymmetric hydrogenation under the same conditions yielding 10 
with 97% of cis product (66 % ee). 
Patil et al. also employed 11 as starting material to produce 5 in a 
“two-step process” with an overall yield of 26% (Scheme 5).[19] The 
first step comprised the formation in situ of the N-acylated 
intermediate 25. Despite the resemblance to the carbamate 
derivatives 22 described on the previous method, the alternative N-
acylation of 11 seems to influence the reaction sequence efficiency, 
since 25 was obtained in 82% in high purity (95%, assessed by 
HPLC) without requiring the intermediates isolation. Intermediate 
25 was further converted in situ into compound 5, by acid treatment 
to give 2 followed by reductive amination with sodium borohydride 
in the presence of titanium (IV) tetraisopropoxide (TTIP). The 
authors also elucidate the formation of the four stereoisomers of 10, 
observing that 1,3-diaxial interactions hinder the formation of trans 
isomers. Resolution with L-DTTA produced the desired compound 
5 in 37% yield (98.6% ee, assessed by chiral GC). The process 
presents some advantages, such as the absence of expensive 
metal catalysts, not requiring the isolation of four intermediates 
without influencing the required API purity. Rao and Zhang also 
reported a similar sequence involving the protection of 11 with Boc, 
however without mentioning the corresponding ee.[20] 
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Scheme 4. Pfizer’s approach (2007) to produce compound 10 from 12.[18] 
 
 
Scheme 5. Patil’s “two-step process” to produce compound 5 from 11.[19] 
Hashmi et al. (Ranbaxy Laboratories Ltd) disclosed a procedure 
involving the bromination of 4-methylpyridine 7, followed by 
quaternization, a copper-catalysed amination of intermediate 27 
and a final reductive step to attain 10 (Scheme 6).[21] However, the 
authors do not provide any information about the ee or dr obtained. 
In 2014, Stavber and Cluzeau (Lek Pharmaceuticals) disclose 
several alternative approaches to attain 10 (Scheme 7).[22] Within 
the methods described, 10 could be obtained from compound 8 by 
direct amination to attain 29 followed by dehydration to give the 
corresponding endo and exo compounds 30. The reduction was 
tested using different conditions, being observed the best cis:trans 
ratio (1.9:1) using the Rh/C catalyst.  
 
Scheme 6. Hashmidi’s procedure involving the bromination of 7 and a copper-catalysed amination to produce 10.[21] 
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Scheme 7. One of the approaches disclosed by Stavber and Cluzeau to obtain 10.[22] 
Very recently, it was reported the asymmetric synthesis of 10 from 
chiral 1,3-dioxolanone (31) (Scheme 8).[23] The work takes 
advantage of preliminary studies, in which the authors report the 
preparation of 31 via a stereoselective Michael addition of the 
corresponding enolate of chiral 1,3-dioxolanone to methyl 
crotonate with high diastereoselectivity (dr >99:1). Removal of the 
chiral auxiliary and formation of the corresponding diamide 
intermediate 32 was achieved in high yield under neat conditions, 
followed by lactonization to yield 33. Ring expansion was 
performed in the presence of lithium diisopropylamide (LDA) and 
molecular sieves to form 34, requiring the dilution of the reaction 
mixture to improve the yield. To obtain the correct stereochemistry 
on the final compound, 35 had to be oxidized to piperidone 36, 
which was performed by Jones oxidation. Since 36 was unstable, 
the compound was used directly on the reductive amination to 
attain 10 in 54%. This asymmetric approach enables the 
preparation of 10 in a 4:1 cis:trans ratio without the need of chiral 
resolution. 
 
Scheme 8. Liao’s asymmetric approach to attain 10.[23] 
 
Other piperidine analogues were also described. In a long synthetic 
approach involving eight steps, Jiang et al. describe the preparation 
of fragment 10 from L-serine (37) (Scheme 9).[24] This approach 
was inspired by a previous report, which employed D-serine to 
obtain several (3S)-amino piperidine derivatives.[25] The main aim 
of Jiang’s work was the development of various enantiopure 
stereoisomers, where the stereocenter at C3 of the piperidine ring 
is established by the choice of the serine derivative. The strategy 
involved the preparation of tert-butyl (R)-(1-(allyl(benzyl)amino)-3-
methylbut-3-en-2-yl)carbamate (42), followed by a ring-closing 
metathesis reaction using Grubbs II catalyst to deliver the 
piperidine derivative 43. Subsequent hydrogenation resulted in a 
mixture of compounds 44, which were chromatographically 
separated. The authors also used D-serine as starting material to 
produce the corresponding stereoisomers. Reduction of 44b with 
LiAlH4 yielded the desired compound 10.[14] 
An alternative method employs L-malic acid (45) as the chiral pool 
starting material, to attain the Cbz-protected compound 52 
(Scheme 10).[26] Despite the extensive synthetic sequence (16 
steps), the authors claim that the synthetic sequence possessed 
several advantages, such as cheap raw materials, mild reaction 
conditions and an overall yield of 26% yielding the product 54 with 
> 98% ee. 
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Scheme 9. Jiang’s route to attain 10.[24] 
 
Scheme 10. Hao’s route using L-malic acid (45) as starting material.[26]  
In 2011, the same group reported the preparation of a Boc-
protected piperidine 62 from the commercially available ethyl 1-
benzyl-3-oxopiperidine-4-carboxylate hydrochloride (55) (Scheme 
11).[27] The first step comprised the replacement of benzyl by a Boc 
protection, preventing concurrent deprotection in a later step. It was 
then envisaged that the introduction of an auxiliary (R)--
methylbenzylamino group, could induce the desired final 
configuration. After screening different metal catalysts for the 
asymmetric reduction, 55 was obtained in good diastereomeric 
excess using NaBH(OAc)3 in the presence of cobalt(II) chloride 
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(CoCl2) and (S)-(–)-2,2’-p-tolyl-phosphino)-1,1’-binaphthyl [(S)-
TolBINAP] as the catalytic system. Methylation of amine by 
reductive amination followed by the ester reduction yielded 
compound 59. Intermediate 61 was obtained through a Mitsunobu 
reaction followed by a Raney Ni catalysed hydrogenation. Removal 
of the auxiliary group was performed using ammonium formate as 
the hydrogen source to give compound 62 in quantitative yield. The 
latter was obtained in an overall yield of 49% and although stated 
that it was obtained in high enantiomeric excess, the value is not 
described. 
In 2014, the preparation of a trityl-protected derivative from 
compound 11 was disclosed,[28] benefiting from the already 
described approach (see Scheme 3). 
 
Scheme 11. Hao’s route using 55 as starting material.[27] 
It is interesting to mention that preparation of 3-((3R,4R)-4-methyl-
3-(methylamino)piperidin-1-yl)-3-oxopropanenitrile or its 
hydrochloride salt (65) is also described and used to prepare 
tofacitinib-related structures. Babu et al. (Biocryt Pharmaceuticals 
Inc.) describe its preparation from compound 5 (Scheme 12).[16] 
Moreover, Gehringer et al. used a similar strategy in order to 
prepare alternative tofacitinib bioisosteres. Compound 65 was 
employed since some substrates were incompatible with the usual 
hydrogenation conditions used to cleave the benzyl group. 
However, it is also stated that derivative 65 is not stable under 
some conditions.[29] 
Other alternative approaches were described to attain several 
tofacitinib structures with different deuterated patterns (Scheme 
13).[20]  
 
 
Scheme 12. Babu’s approach to attain compound 65.[16] 
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Scheme 13. Rao’s route to attain deuterated tofacitinib derivatives.[20] 
 
An alternative strategy to attain 1 involving a Mitsunobu reaction, 
conducted to the development of a novel piperidine analogue 
(Scheme 14).[30] In 2013, Maricán et al. reported the preparation of 
tert-butyl-(3S,4R)-3-hydroxy-4-methyl piperidine-1-carboxylate 
(81), a key synthetic intermediate obtained in 6 steps from 
compound 75.[31] Preliminary TBDPS and Boc protections followed 
by a selenoxide elimination yielded 78. Compound 79 was obtained 
with a de >94% via a Grignard methyl cuprate addition. Reduction 
followed by silyl group deprotection afforded 81 with an overall yield 
of 18%. 
Alternatively, compound 81 was obtained from crotyl alcohol via an 
eight-step synthetic sequence with a yield of 19% (98% ee).[32] 
 
Scheme 14. Maricán’s approach to produce the alternative intermediate 81.[30] 
 
3. Tofacitinib assembly 
As already mentioned, the retrosynthetic analysis performed for 
tofacitinib (1) can assume two major fragments: the pyrrolo[2,3-
d]pyrimidine moiety and a chiral 3,4-disubstituted piperidine ring. 
Following this idea, the most notorious disconnection can be 
performed either: 1) between the pyrrolo pyrimidine ring and the 3-
amino-4-methyl piperidine moiety or 2) between the 4-amino-
pyrrolo[2,3-d]pyrimidine structure and the piperidine ring (Scheme 
15). In fact, the first reported synthesis of 1, comprised a SNAr 
reaction of 3 with 4-chloro-pyrrolo[2,3-d]pyrimidine (82), also 
known by 6-chloro-7-deazapurine), followed by hydrogenation to 
cleave the benzyl group and a final cyanoacetic side-chain insertion 
involving several approaches (Scheme 16).[4] Due to the easy and 
cheap production of 82 and the convenient benzyl protection of the 
piperidine ring, this simple synthetic sequence was rapidly adopted 
and has been generally employed in most of the subsequent 
reports. 
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Scheme 15. Common tofacitinib disconnections. 
The synthetic sequence to attain tofacitinib (1) usually starts by 
preparing 82 from the cheapest 7-deazahypoxanthine (CAS 
3680-71-5) in good yields,[33] although it can be currently 
purchased from different sources. Compound 82 can also be 
prepared from smaller fragments but with a longer synthetic 
sequence.[16] The nucleophilic substitution of chlorine with 3 (or 
one of its salts) was normally performed at reflux temperature 
employing different conditions, such as K2CO3 in water,[4],[16] 
Na2CO3 in water (sealed tube),[29] or neat in TEA,[34] usually with 
low yields. Alternatively, compound 86 can also be used in the 
SNAr showing better yields than the obtained with 82.[18] 
Chloride displacement occurs under the hydrogenation 
conditions yielding 85. 
In order to enhance the reaction yield and reduce undesired 
impurities, several groups employed a tosyl-protection for 
intermediate 88.[18],[24],[19],[23] Indeed, heating the tosylated 88 
with 5 in water in the presence of K2CO3, yielded 89 in 85% 
(Scheme 17).[19] This protection-deprotection methodology does 
not have a detrimental effect on yield, which may be higher than 
the observed for direct substitution with the piperidine 
intermediate. Detosylation can be simply performed using a 
NaOH aqueous solution.[18] However, it was observed that water 
could promote undesired racemization, which could be 
prevented by using methanol.[19] 
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Scheme 16. General alternatives to attain tofacitinib. 
 
 
 
Scheme 17. Use of tosylated derivative 88 to attain intermediate 84.[19] 
 
Debenzylation of 84 was performed under standard conditions. The 
original hydrogenation conditions used 20% Pd/C in ethanol in the 
presence of HCl.[4] Other conditions employed 20% Pd(OH)2/C in 
H2O/iPrOH/AcOH or in MeOH/TFA, or a combined 20% Pd(OH)2/C-
10% Pd/C system in MeOH.[29] The reaction can be performed at 
room temperature, although the reaction times could be 
significantly decreased employing higher temperatures. 
Installation of the cyanoacetate chain was the transformation that 
showed more diversity in the employed procedures. The first 
described method employed cyanoacetic acid pyrrolidin-1-yl ester 
in ethanol (Scheme 16, A).[4],[34] However, most of the procedures 
rely on the cyanoacetic acid activation employing a proper 
activating agent. Thus different systems were used: 
HATU/iPr2NEt,[24] TBTU/HOBt/DIPEA or EDC/HOBt[30] (Scheme 16, 
B).[29] Alternatively, 1 could be obtained from the corresponding 
acid chloride (Scheme 16, C) or refluxing ethyl cyanoacetate in the 
presence of TEA in toluene (65%).[18] Price et al. also report a 
protocol for direct amidation of alkyl cyanoacetates using 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) in 1-BuOH. The authors 
described a single-step process which does not require a 
preliminary acid activation, avoiding the decomposition of the 
activated acid and reduction of waste, being a good solution for 
large-scale production. Tofacitinib (1) was obtained (as the citric 
acid salt) using 0.5 equiv of DBU within 12 h at 40 °C (90%) 
(Scheme 16, D).[35] 
An alternative coupling of piperidine functionality to the heterocyclic 
moiety was devised from a different retrosynthetic point-of-view. 
The authors report a reaction sequence involving a Mitsunobu 
reaction between the tert-butyl-(3S,4R)-3-hydroxy-4-methyl-
piperidine-1-carboxylate (81) and 90 (Scheme 18).[30] The latter 
was prepared from the corresponding 6-amino-7-deazapurine (83) 
via reductive amination using a HCHO/NaBH3CN system. 
Application of the standard Mitsunobu conditions (Ph3P/DIAD), 
yielded 91 in 68% yield (>94% de). It is worthy to mention, that on 
the opposition to the trendy benzyl-protected piperidine fragment, 
herein the authors presented a Boc-protection, which was cleaved 
using ZnBr2 to yield 85. Coupling of the resulting amine with 
cyanoacetic acid through an EDC/HOBt activation afforded 1 in 
80% yield. The overall yield (9.5%), which includes the preparation 
of 81 (see Scheme 14), overcomes some of the previous 
methodologies. 
Scheme 18. Preparation of tofacitinib via Mitsunobu approach.[30] 
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Conclusions 
This review describes the continuous improvements performed 
on tofacitinib synthesis, particularly on the intricate preparation of 
a key structural feature fundamental to its activity. These synthetic 
efforts indicate the growing importance of this API in different 
therapies and how it is still extensively studied towards several 
pathologies. Moreover, the implementation of convenient 
synthetic strategies in industry is still highly demanding, with 
permanent scouting for efficient and cost-effective solutions 
without forgetting the safety and environmental protection. The 
review covers the literature since the initial attempts to prepare 
this important structure until the recent trends, observing the large 
efforts performed to fulfil these demands. It collects valuable 
information from the different methods and expects to motivate 
other groups to pursue this challenging endeavor. 
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MICROREVIEW 
Tofacitinib is a Janus activated kinase 
(JAK) inhibitor approved for the 
treatment of rheumatoid arthritis and 
active psoriatic arthritis. Its synthesis 
normally involves long synthetic 
sequences due to the chirality 
associated to the piperidine ring. This 
review is a comprehensive analysis of 
the different synthetic methods used 
to prepare this active pharmaceutical 
ingredient (API), covering the related 
journal and patent literature. 
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Tofacitinib synthesis – an asymmetric 
challenge 
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